RxDoctor Payments Data

Richard Whitley

Pediatric Infectious Diseases · Birmingham, ALNPI 1649287871

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,126,259 of the $1,173,821 with a category attached, or 95.9%. Gilead accounts for 91.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $476,085 and has fallen 92.4% since, to $36,353 in 2025.

$1,173,821in general payments, 2019–2025

Across 203 payments — averaging $5782.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1.1M
  • Visby Medical, Inc.$40K
  • Merck$27K
  • GSK$18K
  • Modernatx, Inc.$8K
  • PTC Therapeutics, Inc.$3K
  • plus $965 from 2 others

What the payments were for

  • Consulting fees$1,126,25996%
  • Speaking & faculty fees$3950%
  • Travel & lodging$43,0464%
  • Food & beverage$4,1210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead145$1,076,920
Visby Medical, Inc.8$40,000
Merck24$27,413
GSK18$17,623
Modernatx, Inc.1$8,100
PTC Therapeutics, Inc.2$2,800
Sanofi-aventis U.S. LLC4$570
F. Hoffmann-la Roche AG1$395

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric infectious diseases providers in Alabamato place this figure against a meaningful peer group, so we don't.

Other pediatric infectious diseases in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →